In this week’s solo episode, Nico Misleh of the Nico Misleh Podcast cuts through the confusion and fear around oral estradiol in hormone replacement therapy (HRT). He addresses a question he hears all the time from clinicians and patients: “Is oral estradiol dangerous? Does it increase the risk of blood clots, stroke, heart attack, or cancer?”
Nico walks listeners through the evidence, points out how myths persist, and explains why many providers can safely and confidently use oral estradiol as part of a thoughtful HRT plan. This article summarizes his key points and the studies he highlights, explains the biology behind the debate, and gives practical guidance for clinicians treating women in menopause or post-menopause.
Why The Confusion About Oral Estradiol?
Nico opens by describing the common clinical feedback: many conventional providers were taught that oral estradiol is risky because it passes through the liver first (first-pass metabolism), which can change blood markers and theoretically raise clotting risk. That warning has stuck in many clinicians’ minds.
However, Nico urges providers to look beyond small, early, or observational studies. He stresses that randomized controlled trials (RCTs), the strongest type of clinical evidence, have not shown the dramatic harms that many people fear.
What The Randomized Controlled Trials Actually Show
Nico highlights two important pieces of evidence. First, a large randomized trial from Denmark followed women given oral hormone replacement for a long period. He quotes the study’s conclusion:
“After ten years of randomized treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction without any apparent increase in the risk of cancer, venous thromboembolism, or VTE.”
In other words, in this long-term, randomized study of about a thousand women, oral HRT did not increase the risk of clots or cardiovascular events and was associated with reduced mortality and heart outcomes.
Nico also references a more recent randomized trial from 2022 that specifically measured blood coagulation parameters. The finding was clear:
“During the twelve-month treatment with one milligram of estradiol and one hundred milligrams of progesterone, there were no clinically significant differences in blood coagulation parameters such as antithrombin activity, protein S level, partial thromboplastin activation time, prothrombin time, fibrinogen concentration, and prothrombin index.”
Put simply, in a one-year randomized trial using bioidentical estradiol combined with bioidentical progesterone, nothing in the bloodwork showed a clinically meaningful increase in clotting risk.
So What About The Small Studies That Raised Concerns?
Nico acknowledges that there were smaller observational studies suggesting oral estradiol increased coagulation markers. Those studies deserve attention; they are signals worth investigating. But single small studies, especially observational ones, are vulnerable to confounding and bias. They can show a lab change without proving that the change leads to real clinical events like clots or strokes.
When larger, randomized trials followed people over years, the theoretical lab-based risk did not translate into measurable harm. That’s the crucial distinction Nico presses: changes in lab markers are not the same as actual increases in clinical events.
Why The First-Pass Liver Effect Isn’t Automatically Bad
Much of the fear about oral estradiol comes from the fact that oral hormones go through the liver, which can alter proteins, inflammatory markers, and binding globulins. Nico notes two commonly cited changes:
- Oral estradiol may increase CRP (C-reactive protein), an inflammatory marker.
- Oral estradiol may raise sex hormone-binding globulin (SHBG), which binds testosterone and reduces free testosterone levels.
But Nico reframes this first-pass effect as not purely a problem. For example, oral progesterone’s first-pass metabolism produces allopregnanolone, a metabolite that helps with sleep and mood; that benefit only appears with oral dosing, not sublingual or topical forms. The first-pass effect can produce beneficial metabolites and positive downstream effects.
Clinical Benefits of Oral Estradiol Highlighted
Nico emphasizes that oral estradiol has documented benefits that matter for long-term health:
- Better preservation of bone density and reduced bone loss compared with some other approaches.
- Improvements in lipid profiles, including ApoB and other markers tied to cardiovascular risk.
- Potential benefits in neurocognitive performance.
- Positive effects on overall cardiovascular outcomes in long-term randomized studies.
These benefits contrast with the misconception that oral estradiol is strictly harmful due to first-pass metabolism. The randomized data show benefits without the expected rise in clinical clotting events.
Progesterone Matters, Don’t Give Estradiol Alone
One of the strongest points Nico makes is that estradiol should almost always be paired with progesterone in women who still have a uterus. Progesterone is not optional in most cases; it counters endometrial hyperplasia and also affects inflammatory and coagulation pathways.
The study from 2022 used 1 mg estradiol plus 100 mg bioidentical progesterone and found no changes in coagulation markers. That matters because some of the small concerns from earlier studies may have been related to estradiol given without appropriate accompanying progesterone.
Practical Guidance For Clinicians
Nico speaks directly to practitioners who feel nervous prescribing oral estradiol. His practical advice includes:
- Favor evidence from randomized controlled trials when making clinical decisions.
- Don’t automatically reject oral estradiol because of older dogma; review the randomized data.
- Use progesterone appropriately alongside estradiol for women with a uterus.
- Consider the broader benefits of oral estradiol (bone, lipids, cognition) when discussing options with patients.
- Monitor appropriately but avoid making decisions based only on changes in lab markers without clinical context.
Addressing Clinician Fear and Cognitive Bias
Nico recognizes that clinicians are risk-averse, and rightly so. Providers want to avoid harm and protect their patients and careers. But he also warns against clinging to myths without re-examining the evidence. He calls poor assumptions “cognitive biases” that hold clinicians back from giving patients the best care.
By reviewing high-quality trials and understanding the nuance of first-pass metabolism, clinicians can make informed choices and feel confident offering oral estradiol when it’s appropriate.
Quick Summary: What Nico Wants Clinicians To Remember
- Randomized controlled trials do not show an increased risk of venous thromboembolism (VTE), stroke, heart attack, or cancer from oral estradiol when used as part of HRT.
- Small studies that show increases in coagulation markers are signals but not definitive proof of clinical harm.
- Combining estradiol with progesterone is essential for most women and may modify theoretical risks.
- Oral estradiol has meaningful benefits on bone, lipids, and cognition that deserve weight in clinical decision-making.
- Providers should look at the totality of evidence, especially RCTs, before defaulting to fear-based decisions.
FAQ
Q: Is oral estradiol safe for women who are early postmenopause?
A: Yes. Long-term randomized studies of women who began HRT early in menopause showed reduced mortality and fewer heart failure and myocardial infarction events, with no apparent increase in VTE, stroke, or cancer.
Q: Should estradiol ever be given without progesterone?
A: Almost always no for women with a uterus. Progesterone protects the endometrium and can influence inflammatory and coagulation pathways. Nico stresses the importance of pairing estradiol with appropriate progesterone in most cases.
Q: What about transdermal estradiol? Is it better?
A: Transdermal estradiol is a valid option and can be helpful in specific clinical contexts. However, it is not categorically safer or more effective in every way. Oral estradiol may offer superior benefits for bone, lipid profiles, and neurocognitive outcomes based on available studies.
Q: Should clinicians stop monitoring coagulation markers if they prescribe oral estradiol?
A: No. Clinicians should continue appropriate monitoring based on each patient’s risk profile. Nico’s point is that changes in lab markers alone should not be taken as proof of increased clinical risk when randomized data do not show more events.
Q: Are there women who should avoid oral estradiol?
A: Yes. Women with specific contraindications (for example, a history of estrogen-sensitive cancer, certain clotting disorders, or other clear contraindications) should avoid systemic estradiol or be managed carefully. Clinical judgment and individual risk assessment are essential.
Final Thoughts
Nico Misleh’s message is simple: don’t let outdated dogma or fear stop you from using an effective tool in HRT. Read the randomized trials, pair estradiol with progesterone when needed, and make patient-centered decisions. The data support that oral estradiol, when used appropriately, does not inherently raise the risk of clots, stroke, or heart attack, and it brings clear benefits for bone health, lipids, and cognitive function.
If you’re a clinician and want to dive deeper and receive daily clinical insights, check out Nico’s Daily Newsletter! It’s a practical way to keep learning and to stay updated on real-world HRT strategies and evidence-driven care.
